# Pharmacokinetics, Tolerability and Safety of NEX-18a

> **NCT05048498** · PHASE1 · COMPLETED · sponsor: **Nanexa AB** · enrollment: 2 (actual)

## Conditions studied

- Myelodysplastic Syndromes (MDS)
- Chronic Myelomonocytic Leukemia (CMML)
- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** NEX-18a injection
- **DRUG:** Azacitidine Injection

## Key facts

- **NCT ID:** NCT05048498
- **Lead sponsor:** Nanexa AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-27
- **Primary completion:** 2022-02-10
- **Final completion:** 2022-02-10
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2023-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05048498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05048498, "Pharmacokinetics, Tolerability and Safety of NEX-18a". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05048498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*